IO Administration of Cefazolin

Phase 2Small molecule

TThe Methodist Hospital Research Institute

IO Administration of Cefazolin is one of 51 small molecule programs targeting Total Knee Arthroplasty. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Knee ArthroplastyRecruiting

Total Knee ArthroplastyPhase 2

Recruiting

Competition

Competitive Landscape

66 competitors in Total Knee Arthroplasty

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

26 2

Naropin

FFresenius Kabi USA, LLC

Approved

26 3

Marcaine

IInnocoll

Approved

18 4

Decadron

AAspen Global Incorporated

Approved

18 5

Medrol

Pfizer

Approved

4 6

Lexapro

AbbVie

Approved

1 7

Journavx

Vertex Pharmaceuticals

Approved

1 8

Duragesic

CCephalon

Approved

7 9

MS Contin

HHikma Pharmaceuticals LLC

Approved

7 10

Celebrex

PPhiladelphia Eye Associates

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2035

Phase 1/2Recruiting

Total Knee Arthroplasty

NCT06640491

Clinical

Trials by Indication[1]

Total Knee Arthroplasty1 trial

Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)

Recruiting·TThe Methodist Hospital Research Institute·Phase 1/2·NCT06640491·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IO Administration of Cefazolin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IO Administration of Cefazolin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IO Administration of Cefazolin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Methodist Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe Methodist Hospital Research Institute

IO Administration of Cefazolin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2035

Trials by Indication[1]

Total Knee Arthroplasty1 trial

References

Drug Info

Quick Facts

Related News